Podcast appearances and mentions of Gregory Zuckerman

Founders ✓ Claim : Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- Jim Simons never took a single class on finance, wasn't interested in business, and didn't start trading full time until he was 40. The company he founded —  Renaissance Technologies — has made over $100 billion in profits.Starting out with the heretical belief that there was a hidden structure in financial markets, Jim decided to staff his “crazy hedge fund” with mathematicians, computer scientists, and physicists. He went to great lengths to collect more historic financial data than anyone else, spent a lot of time recruiting “killers” (people with single minded focus that wouldn't quit), invested heavily in computers (and the people who ran them), and designed the most collaborative work environment.Jim was a world-class mathematician, code breaker, exceptional manager of people with exceptional minds, a genius in system design, and deeply understood the power of incentives. He was also incapable of giving up, willing to endure a decade of struggle and pain, and hell-bent on doing something “historic” with his life.Jim Simons lived a life defined by persistence, unconventional thinking, and an unwavering pursuit of excellence. Studying his life and work is time well spent. This episode is what I learned from rereading The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution by Gregory Zuckerman. ----Ramp gives you everything you need to control spend, watch your costs, and optimize your financial operations —all on a single platform. Make history's greatest entrepreneurs proud by going to Ramp and learning how they can help your business control your costs and save more. ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work.  Get access to Founders Notes here. ----Join my free email newsletter to get my top 10 highlights from every book ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work. Get access to Founders Notes here. ----“I have listened to every episode released and look forward to every episode that comes out. The only criticism I would have is that after each podcast I usually want to buy the book because I am interested so my poor wallet suffers. ” — GarethBe like Gareth. Buy a book: All the books featured on Founders Podcast

Jim Simons never took a single class on finance, wasn't interested in business, and didn't start trading full time until he was 40. The company he founded —  Renaissance Technologies — has made over $100 billion in profits.Starting out with the heretical belief that there was a hidden structure in financial markets, Jim decided to staff his “crazy hedge fund” with mathematicians, computer scientists, and physicists. He went to great lengths to collect more historic financial data than anyone else, spent a lot of time recruiting “killers” (people with single minded focus that wouldn't quit), invested heavily in computers (and the people who ran them), and designed the most collaborative work environment.Jim was a world-class mathematician, code breaker, exceptional manager of people with exceptional minds, a genius in system design, and deeply understood the power of incentives. He was also incapable of giving up, willing to endure a decade of struggle and pain, and hell-bent on doing something “historic” with his life.Jim Simons lived a life defined by persistence, unconventional thinking, and an unwavering pursuit of excellence. Studying his life and work is time well spent. This episode is what I learned from rereading The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution by Gregory Zuckerman. ----Ramp gives you everything you need to control spend, watch your costs, and optimize your financial operations —all on a single platform. Make history's greatest entrepreneurs proud by going to Ramp and learning how they can help your business control your costs and save more. ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work.  Get access to Founders Notes here. ----Join my free email newsletter to get my top 10 highlights from every book ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work. Get access to Founders Notes here. ----“I have listened to every episode released and look forward to every episode that comes out. The only criticism I would have is that after each podcast I usually want to buy the book because I am interested so my poor wallet suffers. ” — GarethBe like Gareth. Buy a book: All the books featured on Founders Podcast

Last week, U.S. stocks lost $6.6 trillion in value during a two-day washout after President Trump announced large tariffs on countries around the world. As markets continue to swing, Wall Street leaders are speaking out, including billionaire investor Bill Ackman and JPMorgan Chase executive Jamie Dimon. Host Kate Linebaugh talks with Gregory Zuckerman about the market chaos and how investors are responding.  Further Listening: -Trump's Tariffs Force a New Era in Global Trade  -Trump 2.0: Trade Wars and Deportation Battles  Sign up for WSJ's free What's News newsletter . Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Mar. 17. Condo sales are falling through when would-be buyers find that the property they want to purchase is on a mostly secret mortgage blacklist maintained by Fannie Mae. WSJ insurance reporter Jean Eaglesham tells us about the list and why it is growing. Plus, President Trump lays the groundwork for investigating people pardoned by President Joe Biden. And recent market volatility is leaving even hedge funds floundering. We hear from WSJ special writer Gregory Zuckerman about the funds' impact on the broader market and what signals they will be looking at in the near future. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Youtube - https://youtu.be/uPU6hJsvMcMCurious Worldview Newsletter - https://curiousworldview.beehiiv.com/subscribeGregory Zuckerman is one of the Wall Street Journal GOATS and as well has authored plenty of wonderful books. He pulls back many of the hidden curtains of wall st. The big egos, the big enigmatic personalities, and naturally as well, the big brilliance behind these masters of the universe types. None for emblematic than Jim Simon's, the central character of todays podcast.Theres a podcast called, Acquired, which did a fantastic episode of RenTech (if you want more), the boys over there also relied heavily on Greg's work to put the episode together. 00:00 - Gregory Zuckerman01:27 - Secrecy All The Way Down06:27 - Acquired08:02 - Obscure Datasets15:07 - It Will Take Longer Than You Think20:04 - Jim's Eye For Talent22:27 - Discoveries From Within RenTech28:54 - Greg's Admiration For Jim & 50+ Year Olds Making It35:27 - Nassim Taleb39:01 - Consequences Of Size41:47 - Acquired Podcast & Bob Mercer44:07 - Politics Infecting Interpersonal Dynamics46:07 - Super Quants Can't Recreate RenTech50:47 - Journalism As Sales53:17 - How Does One Conduct A Good Interview?57:37 - The Most Important Question About RenTech Noone Asks59:13 - Decline Of Journalism1:11:14 - The Role Of Serendipity In Greg's Life

Chris Rongey and Amy Marxkors explore the rapid advancements in the AI sector, focusing on the rise of DeepSeek, a Chinese AI company claiming to have developed a superior model at a fraction of the cost compared to industry leaders like OpenAI. Wall Street Journal's Gregory Zuckerman shares insights into DeepSeek's founder, Liang Wenfeng, and his background in quantitative investing. They discuss the impact of DeepSeek on tech stocks, AI market dynamics, and the geopolitical ramifications, including its role in a new potential "Cold War."

THE HASTE WAS THE KNOWN RISK: 7/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 TOKYO

PREVIEW: Conversation with author Gregory Zuckerman in 2021 for his "A Shot to Save the World," re the haste that skipped adequate sized and demographic trials for the vaccines -- leading to lots of doubts about side effects. More later. 1918 DC

PREVIEW: Conversation with author Gregory Zuckerman in 2021 for his "A Shot to Save the World," re the race for a COVID vaccine, and how the years of blind alleys for some, and frustration with the monetizing of vaccines, as compared to drugs, delivered the breakthrough. More later. 1918 DC

THE HASTE WAS THE KNOWN RISK: 8/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 CAMP FUNSTON

THE HASTE WAS THE KNOWN RISK: 6/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 NSW AUSTRALIA

THE HASTE WAS THE KNOWN RISK: 5/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 QUEENSLAND AUSTRALIA QUARENTINE CAMP

THE HASTE WAS THE KNOWN RISK: 4/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 ST. LOUIS

THE HASTE WAS THE KNOWN RISK: 3/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 SEATTLE

THE HASTE WAS THE KNOWN RISK: 2/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 COLORADO

THE HASTE WAS THE KNOWN RISK: 1/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 CAMP FUNSTON, KANSAS

For episode 34 of the Bao Podcast, we invited once again a familiar face. He was one of our first guests, and is back today: Arne Allewaert. Arne is a co-founder and Managing Partner at AMAVI Capital.  AMAVI is a fully independent investment fund with a pan-European scope, established to support the growth of the leading and most promising scale-ups active in the PropTech industry. AMAVI bridges the traditional real estate industry on the one hand and European PropTech scale-ups on the other. AMAVI Capital (https://amavi.capital/) YouStock (https://www.youstock.com/) Casafari (https://www.casafari.com/)   Team.blue (https://team.blue/)  Enpal (https://www.enpal.de/)  Cintoo (https://cintoo.com/)  Shayp (https://www.shayp.com/)  Hydraloop (https://www.hydraloop.com/)  ‘The Last Dance' on Netflix (https://nl.wikipedia.org/wiki/The_Last_Dance)  ‘The Man Who Solved the Market' - Gregory Zuckerman (https://www.goodreads.com/book/show/43889703-the-man-who-solved-the-market)  Time stamps: 0:00 Intro 1:30 Biggest changes and lessons since previous episode 19:55 Looking for opportunities in certain verticals 31:00 Companies on the forefront of sustainability 39:00 Some of the companies in the AMAVI portfolio  42:00 Water investments 45:30 Outro

In this episode, Gregory Zuckerman joins us to discuss his book, The Man Who Solved the Market, which chronicles the remarkable journey of Jim Simons. Simons, a mathematician turned investor, co-founded Renaissance Technologies and achieved an astonishing 66% annual return before fees with his Medallion Fund. Zuckerman sheds light on Simons' systematic trading approach, blending advanced algorithms with human intuition. He also addresses the role of AI in modern finance, emphasizing that while technology is crucial, human insight remains essential. Additionally, Zuckerman talks about his other works which aim to inspire young people through stories of overcoming adversity. Tune in to gain insights into the intersection of human and machine in finance and the power of inspirational storytelling.

P.M. Edition for Aug. 12. The rapid decline of several popular trades and the heavy use of leverage sparked last week's markets meltdown. WSJ special writer Gregory Zuckerman breaks down how borrowed money and risky bets set off a stock-market roller coaster. And Heard on the Street columnist Jinjoo Lee explains why the AI boom could cause a hike in Americans' power bills. Plus, Israel puts its military on high-alert on the possibility of an attack by Iran and Hezbollah. Francesca Fontana hosts.  Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Gregory Zukerman writes for the Wall Street Journal. Over the last few decades he has written several books. In 2019 he wrote "The Man Who solved the market: How Jim Simons Launched The Quant Revolution" which became a runaway hit. It tells the story of a genius mathematician who used modern quantitative techniques to make money for himself and his investors. Since 1988 one of the fund's operated by Mr Simons generated average annual returns of 66%. Legendary investors like Warren Buffet, George Soros and Peter Lynch, too, cannot claim to have made these outsized profits with such consistency. How did Mr Simons go about his business? How did he manage a stellar team while keeping them movitated? How did he use machine learning, artificial intelligence, data and analytics in an era when these terms were unheard of in the industry? Gregory Zukerman explains it all in this podcast.

Good day, good day, everybody. Brian here from wantlabs.net. Today is May 28th. I'm going to have some big news coming down the pipe soon. So keep your eyes and ears and all that peeled out for it. Anyways, I came across another interesting article. I do like this BetterSystemTrader.com podcast. It's pretty good. They did a posting called 10 Insights from the Man Who Solved the Market. This is referring back to the book Jim Simons Medallion Fund. It's the book put out by Gregory Zuckerman a few years ago. So this guy, Andrew Swan Scott, read it and thought he'd provide his insights. So let's go through these.   Get your free trading tech books here books2 - QUANTLABS.NET The first one is originality matters. Ignore conventional wisdom about the markets. Innovate and explore unique trading strategies and ideas. Look at the market differently from the herd. I totally agree with that because when you look at the markets, there's usually a star performer out there if you go out and dig for that among all the different data sources. And it could be a long-term trending strategy that you could use based on that. A good one in the past was USD Japanese Yen. Another one that was lesser known was USD Turkish Lira or Euro Turkish Lira. They did really good over the years, but now central bankers have stepped in and taken away those opportunities. Now, I don't know about the yen. That could continue, but that could lead to something that could be the next big catalyst to take us all down. But at the end of the day, looking for those sort of things, finding them, that's what gives you what they call trading edge for sure. Number two, collaborative success. Partner with talented individuals. Foster a collaborative environment to enhance problem-solving and innovations. Again, I cannot stress this. We're hoping to have an interview with Ernie Chan and other people that have kind of trailblazed the whole quant trading space, specifically for those that are coming from the retail trading space. Because as we know, to do true HFT, high-frequency trading, and true low-level quant research and that, people can kind of do it, but you have to have a fairly big account to take advantage of it to really do the pay-to-play thing directly right on the exchanges. As a retail trader going through a retail trading broker, that's pretty hard to do. So you have to find people that are kind of in the same area as you in terms of your account size, maybe your technical chops, as well as your mathematical experience. For myself, I guess I can share this now is that I will be moving my site over to a better technology, to Wix. I'm hoping to build out a better group community through that. That's part of the WIC's features, I guess. I did have an amazing group a few years ago. They're still around. I just want to bring more people together so that they can engage with each other behind the scenes. All at a paywall, but membership privileges have its costs. So that's where you get the collaborative success. So that's what I'm hoping to bring to the table. Okay, number three, embrace scientific rigor. Apply a rigorous scientific approach in model Model testing and validation ensuring robustness and statistical significance. This isn't really HFT, but to make life easier for a retail trader, I find using tools, very popular, very in-depth tools like TradingView helps you here. You can see instantly without going through any of the wonky backtesting packages out there, frameworks. works. Out of the box, you're ready to go. When you're working with an open source trading strategy, if you build your own, buy one, lease one, whatever on TradingView, you get the ability to see it. What's its profit potential? What is its profit factor? Which is another way of saying, if I'm going to put a dollar in, how much can I expect to get return from that via the profit factor? These are right there out of the box. So when you have these sort of instantly viewable to you from a high level, it makes your life a lot easier and a lot less stressful. A lot of people want to build and roll their own solutions. I'm not against that. But when you get up to my age, you will start to see how valuable time will be. That's all I could tell you. Efficient capital allocation. Okay. Develop systems to optimize capital allocation across various strategies to maximize returns and manage risk. One thing I can mention here, a lot of the boutique hedge funds, boutique AGFT shops, a lot of them will trade in the space of options. I don't think you can operate under a really successful trading strategy with a $1,000, $5,000 account. You need to have something fairly significant to play those kind of, I don't want to say gains, but kind of strategy capabilities. You need probably $20,000, $25,000 because you have to add all your premium and all that fun stuff. And that's why one of the reasons why ETFs are popular because they're not really risky. You can dream like a stock and there's no margin requirement any of that so these sort of things matter but if you do do the options training you can do very well if you get something that actually actually works okay let's talk number six leverage with caution use leverage strategically to amplify your returns now most people i talk to who keep their account in check from early blowing up. One of the things they do is they use no more than six times. I've seen in crypto years ago, finance would have 100 times and so on. And that's high risk when things are not going your way, especially when the assets are in a consolidation phase or downward spiraling or falling knife environment. You don't want to use leverage there. If it's a long-term trend and it's doing well, then yeah, add your leverage. Some people may go up to 12, let's say, but no more will not go more than six. Data quality is key. Prioritize the acquisition and cleaning all extensive data sets for accurate model development and testing. Again, this is where I like TradingView. you. You can get all kinds of data sources. You'll get, let's say if you're using free data sources like Yahoo Finance, expect to get the gaps. The gaps are going to be deadweight to you and they're going to be hard to work with. So you got to use good quality data. Obviously, there's lots of sources and most of them, I think all of them are going to be paid. And if you're not willing to do that, you're going to, I don't know, if you're just playing around and experimenting, fine. But if you ever want to get serious, you got to pay for the data. And as I say what you get what you pay for is what you get so if you're going to get free stuff I expect to have a low quality. Experiences and results that's all I can tell you they have the ability to enable you to have. Enable you to have decent success there. But obviously, you got to find your proper strategy. Short-term focus, number eight, concentrate on short-term trading opportunities where predictive power is stronger and more actionable. I know one successful trader, he most likely will hear this, he's trading on one minute. Now, he's probably successful there based upon his experience, based upon his history, and he's probably blown up a lot of accounts. So the short focus can help, but this is, again, for a guy who's built and defined high-frequency trading. And obviously, sub-second, sub-minute matters if you're successful. If you're coming from the free trade world, you want to work with basically. Basically long-term, daily, four-hour. When I was writing for Seeking Alpha, they wouldn't accept articles that timeframes less than four hours. So that's just to give you a scenario depending upon who you are and where you're coming from in terms of knowledge in the world of trading. Execution matters. Invest in technology and processes for efficient trade execution to minimize market impact and slippage the one i've come up with between trading view and the auto trading that's how trading view defines it with something like traders post is exceptional i could be sleeping at night and it trades and it's 100 fully synced that's all i can tell you there unless you try it you're not going to know except luck's rule there is a lot of luck i'm not going to deny that to you and yeah so we'll leave it at that you know basically it's like betting in a casino where if you're betting. If you're betting in Vegas, well, that means you may be riding on luck. You may have to do 10 little trades, take 10 little losses, but maybe that 11th trade may be the big one that you're seeking. But how often does that happen? No one knows. If you have a strategy that may be able to predict that, fine. And then you can work off of that for luck. So basically what this guy was saying, the author of this article here, Peter, this Andrew guy said, what Simmons, Simons and his team achieved is remarkable. We'll probably never see anything like this in our lifetime. Who knows? Computers may come up and do stuff and they may be doing it already through the AI, but we just don't know about it because these are not publicly known. They're not going to go on the internet and say, hey, look at me. I bought a Ferrari because I made an amazing AI trading solution. And if they are, they're just probably BSing. And if they're not showing they're creating journal to achieve that, well, there's a problem there. We may never know the details, but there are enough hints to guide all traders. Very true. Yeah. And then there's interview posted here with the guy, Gregory Zuckerman. Also, I think I can say about this is that Simons was very reluctant to do the interview and to do the book. And apparently, there are some parts in the book that Simons didn't want to get revealed. But this Zuckerman still went ahead and published it. And I don't think Simons was too happy about it. I wanted to leave that as well. And I'll talk to you soon. Have a good day. Remember, get on our training books, quantlabs.net slash books. That may change soon. So do it while you can. Over and out. Thank you.

P.M. Edition for May 17. The Dow officially closed above 40000 today, for the first time ever. Special writer Gregory Zuckerman explains why investors are striking gold—and how long it could last. And Heard on the Street columnist David Wainer has more on why the Medicare bubble may have burst. Plus, workers at a Mercedes-Benz plant in Alabama reject unionization, in a setback for the United Auto Workers union. Annmarie Fertoli hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jim Simons pioneered a revolution in financial trading, embracing a computer-oriented, quantitative style in the 1980s well ahead of Wall Street. Following Simons' recent death, WSJ's Gregory Zuckerman unpacks his legacy from financial algorithms to philanthropy.  Further Reading: -How Did Jim Simons's Firm Make $100 Billion? He Told His Secrets to Our Reporter  -Jim Simons, a Pioneer of Quantitative Trading, Dies at 86  -The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution  Further Listening: -Charlie Munger: Curmudgeon, Sage and Investing Legend  -Rise and Revolt at Renaissance, Part 1  -Rise and Revolt at Renaissance, Part 2  Learn more about your ad choices. Visit megaphone.fm/adchoices

Gregory Zukerman writes for the Wall Street Journal. Over the last few decades he has written several books. In 2019 he wrote "The Man Who solved the market: How Jim Simons Launched The Quant Revolution" which became a runaway hit. It tells the story of a genius mathematician who used modern quantitative techniques to make money for himself and his investors. Since 1988 one of the fund's operated by Mr Simons generated average annual returns of 66%. Legendary investors like Warren Buffet, George Soros and Peter Lynch, too, cannot claim to have made these outsized profits with such consistency. How did Mr Simons go about his business? How did he manage a stellar team while keeping them movitated? How did he use machine learning, artificial intelligence, data and analytics in an era when these terms were unheard of in the industry? Gregory Zukerman explains it all in this podcast.

A conversation with Gregory Zuckerman, an award-winning writer for The Wall Street Journal and author of "The Man Who Solved Wall Street". We dive deep into the world of quant investing, exploring the journey of renowned mathematician, investor, and Founder of Renaissance Technologies, Jim Simons, together with his extraordinary team.  Watch it on YouTube https://youtu.be/_5JkBUeLOLQ REFERENCES ▶️The book: https://www.waterstones.com/book/the-man-who-solved-the-market/gregory-zuckerman/9780241309735 ▶️Greg's website: https://www.gregoryzuckerman.com/ ▶️ Follow Greg on Twitter: https://twitter.com/gzuckerman? TO GO FURTHER

Efficiency experts say you must plan your work and work your plan. And you must have written goals and a budget and a schedule.A detailed plan is the key to success when you are doing something small, but you cannot have a detailed plan when you are doing something big and new and untried.You know a project is small when all the variables can be known in advance.When you do something big and new and untried, you will come to a place that your plan did not foresee. This is when you must improvise. Later, you will discover that you are making decisions at the last moment, because that is when you have the most information.Possibilities are in your mind. Reality is at your fingertips. So get started. Move. Take action. Do something.Clarity, commitment, and continual improvement are what you need most when doing something big and new and untried.1: Clarity means you have a clear vision of the outcome you are hoping to bring into reality.2: When you have clarity, you always know what to do next.3: Commitment means that quitting will never occur to you.4: When you have commitment, you find a solution to every obstacle.5: Continual Improvement means that you touch your project every day without fail.6: Touching your project every day – and moving it forward a little – unleashes the power of Exponential Little Bits, the energy that spins your flywheel.7: A thousand tiny touches don't add up, they multiply. Two becomes four. Four becomes eight. Eight becomes sixteen, and 28 cycles later you have exceeded one billion.8: The only things you cannot know in advance are(A.) How long is it going to take?(B.) How much is it going to cost?9: If you insist on knowing those answers in advance, these are the answers:(A.) It will take as long as it takes(B.) It will cost what it costs.10: If you demand answers with more details, you either lack commitment or you believe I can see the future.11: I cannot see the future.12: The only hard part is step number one.You will notice I have given you a 12-step program. This is because doing things that are big, new, and untried is highly addictive, and every addictive thing has its own 12-step program.Do not confuse it with a plan.Roy H. WilliamsPS – George Bernard Shaw said, “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” Roy might tell you more about George Bernard Shaw next week. Or then again, maybe not. – IndyCharlie Munger was the billionaire businessman who built Berkshire Hathaway side-by-side with Warren Buffett. Just weeks before Munger died at age 99, Gregory Zuckerman of The Wall Street Journal spent 4 hours with Charlie in the billionaire's Los Angeles home and came away with some life-changing insights. This week, roving reporter Rotbart interviews the last journalist to interview Charlie Munger, which makes everyone who listens to this week's episode of Monday Morning Radio just three degrees of separation from Charlie Munger and four degrees from Warren Buffett. How can you resist? This party will start the moment you arrive at MondayMorningRadio.com.

Can you imagine what it would have been like to have an exclusive four-hour audience with the late Charlie Munger?  The billionaire businessman, who died in late November at age 99, never got as much press as his close friend and partner Warren Buffett. But many people credited Munger with helping secure Berkshire Hathaway's decades-long stellar investment performance. Just weeks before Munger passed, The Wall Street Journal veteran reporter Gregory Zuckerman visited Munger in the investor's Los Angeles home and came away with some unique and actionable insights.  This week, award-winning author and Monday Morning Radio founder Dean Rotbart interviews the last journalist to interview Munger. That makes everyone who listens to this week's episode only three degrees of separation from Munger and four degrees from Buffett. It's always nice to know people who know people. And, importantly, to learn what they know. Monday Morning Radio is hosted by the father-son team of Dean and Maxwell Rotbart. Photo: Greg Zuckerman, The Wall Street JournalPosted: January 8, 2024Monday Morning Run Time: 37:06Episode: 12.27 To show your appreciation for Monday Morning Radio and keep it commercial-free, we encourage you to contribute using this link. Donations of all sizes are welcome.

On today's episode, we revisit a conversation we had with two pioneers of the mRNA-based Covid-19 vaccines, Katalin Karikó, PhD, and Drew Weissman, MD, PhD. The two were just awarded the 2023 Nobel Prize in Physiology or Medicine for their groundbreaking research in messenger RNA (mRNA) technology. When we spoke with Dr. Kariko and Weissman in June 2022, they had just received the Ross Prize in Molecular Medicine. The Feinstein Institutes for Medical Research grants this honor to recognize promising careers in the fields of science and research. In this look back on that conversation, the history-making duo discusses what motivated them to endure their decades-long scientific struggles, plans to continue their mRNA research and what it means to be awarded the Ross Prize. Also on the show, we speak with Kevin Tracey, MD, president of the Feinstein Institutes for Medical Research, about the importance of supporting young scientists, early-stage research and the culture of science. Meet the experts Katalin Kariko, PhD, adjunct professor of Neurosurgery at the University of Pennsylvania and a senior vice president at BioNTech Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research in Penn's Perelman School of Medicine The award Drs. Kariko and Weissman received is one of six categories that are recognized each year. Since 1901, there have been 114 prizes in the Physiology or Medicine category awarded to 227 laureates.  Learn more about the Nobel Prize  Learn more about Drs. Kariko and Weissman.  More on the history of mRNA technology Learn more about the history of mRNA technology and the development of the Covid-19 vaccines on this episode of the podcast, featuring Wall Street Journal writer, Gregory Zuckerman, and two of the first Americans to receive the vaccine, Sandra Lindsay and Yves Duroseau, MD.  Watch episodes of 20-Minute Health Talk on YouTube. 

George Soros, the legendary investor, philanthropist and right-wing target, is handing control of his $25 billion empire to his fourth child—Alexander Soros, a former party boy and self-described center-left thinker. WSJ's Gregory Zuckerman on how Alex Soros plans to deploy his family's vast fortune. Further Reading: - George Soros Hands Control to His 37-Year-Old Son  - The Soros Era Is Over on Wall Street  Interested in other succession stories? Listen to: - The World's Richest Person Is Planning for Succession  - Scholastic's Succession Drama  Learn more about your ad choices. Visit megaphone.fm/adchoices

Early staffers at Sam Bankman-Fried's first company, Alameda Research, say they quit over his approach to risk, compliance and accounting. How similar were those issues to ones that arose at the crypto exchange FTX? Wall Street Journal special writer Gregory Zuckerman joins host Zoe Thomas to discuss what happened at Alameda and how much it foreshadowed FTX's downfall. Learn more about your ad choices. Visit megaphone.fm/adchoices

Photo: No known restrictions on publication. @Batchelorshow MrMarket: FTX blows up in predictable tomfoolery. Gregory Zuckerman, WSJ. https://www.wsj.com/articles/ftx-hires-ex-regulators-to-investigate-firms-collapse-11669233784

Gregory Zuckerman has been a Special Writer at The Wall Street Journal for over 25 years and is a three-time winner of the Gerald Loeb award — the highest honor in business journalism. He's also written 5 books on a variety of topics which have won a number of awards and been translated into additional languages. At the Journal, Greg writes about big financial firms, personalities and trades, hedge funds, the energy revolution and other investing and business topics. Previously, Greg was the lead writer of the widely read “Heard on the Street” column and covered the credit markets, among other beats. Greg appears regularly on CNBC, Fox Business, Yahoo Finance, Bloomberg Television and various television networks. He makes regular appearances on National Public Radio, BBC, ABC Radio, Bloomberg Radio and radio stations around the globe. Greg gives speeches to business groups on a variety of topics. He has spoken to groups in New York, Los Angeles, San Francisco, Houston, Dallas, Las Vegas, Phoenix, Calgary, Montreal and Niagara Falls. Check out his full bio and his amazing books at: https://www.gregoryzuckerman.com/ Keep up with the podcast on Twitter @Jews_Shmooze and to sponsor an episode, reach out to JewsShmoozeMarketing@gmail.com

Photo: #Markets: Black Swans every Perfect Storm. Gregory Zuckerman, WSJ. https://www.wsj.com/articles/black-swans-and-perfect-storms-wall-street-reaches-for-cliche-to-excuse-your-withered-401-k-11657206520?mod=Searchresults_pos1&page=1

Photo: No known restrictions on publication. @Batchelorshow 4/8:  Still a miracle.By  Gregory Zuckerman. 4/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 8/8:  Still a miracle.By  Gregory Zuckerman. 8/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 7/8:  Still a miracle.By  Gregory Zuckerman. 7/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 6/8:  Still a miracle.By  Gregory Zuckerman. 6/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 2/8:  Still a miracle.By  Gregory Zuckerman. 2/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 5/8:  Still a miracle.By  Gregory Zuckerman. 5/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 3/8: Still a miracle.By  Gregory Zuckerman. 3/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 1/8:  Still a miracle.By  Gregory Zuckerman. 1/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Our guest this week is Mary Childs. Mary is a cohost and correspondent for National Public Radio's Planet Money. Previously, she was a reporter at Barron's magazine and before that, a reporter at the Financial Times and Bloomberg News. She received her bachelor's degree in business journalism from Washington & Lee University. Mary is the author of a new biography about the iconic Pimco bond fund manager, Bill Gross. It's called the The Bond King: How One Man Made a Market, Built an Empire, and Lost It All. We spent this episode delving into the book with Mary's help.BackgroundBioPlanet Money podcastThe Bond King: How One Man Made a Market, Built an Empire, and Lost It All, by Mary ChildsPimco Total Return Analyst ReportEarly Life and CareerBeat the Dealer, by Ed Thorpe“The Strange Billionaire Who Revolutionized the Bond Market,” by Greg Rosalsky, npr.org, March 15, 2022.“Bill Gross Made the Bond Market What It Is Today,” by Mary Childs, barrons.com, Feb. 8, 2019.Psychology and MotivationsJeffrey Gundlach“Gross Friendly to Fannie and Freddie,” by Bloomberg News, investmentnews.com, Oct. 31, 2011.“Pimco Shook Hands With the Fed—and Made a Killing,” by Reuters, cnbc.com, Sept. 27, 2013.“Special Report—The Twilight of the Bond King,” by Jennifer Ablan and Matthew Goldstein, reuters.com, Feb. 9, 2012.“Announcing the Morningstar Fund Managers of the Decade,” by Karen Dolan, Morningstar.com, Jan. 12, 2010.“Fall of the Bond King: How Gross Lost Empire as Pimco Cracked,” by Mary Childs, Bloomberg.com, Dec. 2, 2014.“Inside the Showdown Atop Pimco, the World's Biggest Bond Firm,” by Gregory Zuckerman and Kirsten Grind, wsj.com, Feb. 24, 2014.“Pimco Dissidents Challenge Bill Gross in ‘Happy Kingdom,'” by Mary Childs, Bloomberg.com, July 8, 2014.“Gross: Economy Can't Survive Much Higher Rates,” keynote presentation at the Morningstar Investment Conference, Morningstar.com, June 25, 2014.Gross' Departure From PimcoMohamed El-Erian“Exclusive: Pimco's Gross Declares El-Erian Is ‘Trying to Undermine Me,'” by Jennifer Ablan, reuters.com, March 6, 2014.“5 Years Later: Pimco Total Return,” by John Rekenthaler, Morningstar.com, June 26, 2018.“Pimco in the Post-Gross Era,” by Eric Jacobson, Morningstar.com, Dec. 26, 2017.“Gross Loses Pimco Power Struggle With ‘Stunning' Exit,” by Mary Childs and Alexis Leondis, Bloomberg.com, Sept. 26, 2014.

Photo: No known restrictions on publication. @Batchelorshow 4/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 6/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 5/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 7/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 3/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 2/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 1/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed

Photo: No known restrictions on publication. @Batchelorshow 8/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed